Home › Research › Cognitive tests and assessment
An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease
Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M.. European journal of neurology, 2008-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and purpose Ginseng is one of the most popular herbs worldwide. Ginseng has various medical applications, and it seems to have significant effects as a cognition-enhancing drug. In this study, we examined the efficacy of Korean red ginseng (KRG) as an adjuvant therapy to conventional anti-dementia medications in patients with Alzheimer's disease.
What this study adds
Evidence grade: High
This is a trial of 15 participants. This 12-week randomized trial gave 61 Alzheimer's disease patients Korean red ginseng at different doses as an add-on to conventional anti-dementia medications. The available text does not report whether ginseng improved cognition.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Heo, J. H., Lee, S. T., Chu, K., Oh, M. J., Park, H. J., Shim, J. Y., et al. (2008). An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. European journal of neurology. https://doi.org/10.1111/j.1468-1331.2008.02157.x
Vancouver
Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, et al. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. European journal of neurology. 2008. doi:10.1111/j.1468-1331.2008.02157.x. PMID: 18684311.
BibTeX
@article{heo2008-18684311,
author = {Heo, J. H. and Lee, S. T. and Chu, K. and Oh, M. J. and Park, H. J. and Shim, J. Y. and Kim, M.},
title = {{An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease}},
journal = {European journal of neurology},
year = {2008},
doi = {10.1111/j.1468-1331.2008.02157.x},
pmid = {18684311},
url = {https://doi.org/10.1111/j.1468-1331.2008.02157.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Ginseng has various medical applications, and it seems to have significant effects as a cognition-enhancing drug.
- In this study, we examined the efficacy of Korean red ginseng (KRG) as an adjuvant therapy to conventional anti-dementia medications in patients with Alzheimer's disease.
- Methods The trial was designed as a 12-week randomized study.
- Sixty-one patients (24 males and 37 females) with Alzheimer's disease were randomly assigned to one of the following treatment groups: low-dose KRG (4.5 g/day, n = 15), high-dose KRG (9 g/day, n = 15) or control (n = 31).
Why it matters
This 12-week randomized trial gave 61 Alzheimer's disease patients Korean red ginseng at different doses as an add-on to conventional anti-dementia medications. The available text does not report whether ginseng improved cognition.
Study details
- Participants15
- Evidence strengthHigh
How this study scored 59/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European journal of neurology) |
| Journal's citation record | 2 / 4 | European Journal of Neurology: journal h-index 181 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 15 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 177 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.8 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 2 / 6 | Cited 2.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mi-Kyung Kim: h-index 33 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Seoul National University: institution h-index 1,053 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18684311) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.